Prothena plummets after amyloidosis failure

By Jaime De Leon | Apr 23, 2018 | 3:13 PM GMT

Prothena Corp. plc (NASDAQ:PRTA) sank $25.34 (69%) to $11.50 on Monday after it discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary endpoints in the Phase IIb